New combo pill could shrink fatty liver and shed pounds
NCT ID NCT07466017
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS060380 for 16 more weeks. The goal is to see if the drug reduces liver fat and body weight safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CS060380 (an experimental drug) plus semaglutide (a weight management drug)
What this could lead to
If it works, this could lead to a new treatment that reduces liver fat and body weight in people with MASH and obesity.
What could go wrong
This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Jiangning Hospital
RECRUITINGNanjing, Jiangsu, 211100, China
Contact Phone: •••-•••-••••
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200001, China
Contact Phone: •••-•••-••••
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-••••
-
Shanghai First People's Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Ningbo University
RECRUITINGNingbo, Zhejiang, 315010, China
Contact
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-••••
-
The First Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050031, China
Contact Phone: •••-•••-••••
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230601, China
Contact Phone: •••-•••-••••
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-••••
-
The Third Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510150, China
Contact Phone: •••-•••-••••
-
Tongren Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200336, China
Contact Phone: •••-•••-••••
-
Zhejiang Provincial People's Hospital
RECRUITINGHangzhou, Zhejiang, 310014, China
Contact